Abliva AB (publ)
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic … Read more
Abliva AB (publ) - Asset Resilience Ratio
Abliva AB (publ) (NEVPF) has an Asset Resilience Ratio of 42.95% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2022)
This chart shows how Abliva AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Abliva AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $78.95 Million | 42.95% |
| Total Liquid Assets | $78.95 Million | 42.95% |
Asset Resilience Insights
- Very High Liquidity: Abliva AB (publ) maintains exceptional liquid asset reserves at 42.95% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abliva AB (publ) Industry Peers by Asset Resilience Ratio
Compare Abliva AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Abliva AB (publ) (2014–2022)
The table below shows the annual Asset Resilience Ratio data for Abliva AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 42.95% | $78.95 Million | $183.83 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $115.31 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $120.11 Million | -- |
| 2016-12-31 | -0.07% | $-118.00K | $180.72 Million | +0.02pp |
| 2015-12-31 | -0.08% | $-148.00K | $174.93 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $131.27 Million | -- |